A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
Clinical trial NCT05919823 · COMPLETED
Trial details
- NCT number
- NCT05919823
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-29
- Primary completion
- 2024-09-16
- Enrollment
- 202
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.